Rocky Mountain Alzheimer's Disease Center Longitudinal Biomarker and Clinical Phenotyping Study



Status:Recruiting
Conditions:Alzheimer Disease, Cognitive Studies, Other Indications
Therapuetic Areas:Neurology, Psychiatry / Psychology, Other
Healthy:No
Age Range:18 - Any
Updated:12/29/2018
Start Date:February 2016
End Date:December 2030
Contact:Nicola Haakonsen
Email:nicola.haakonsen@ucdenver.edu
Phone:303-724-4644

Use our guide to learn which trials are right for you!

Rocky Mountain Alzheimer's Disease Center at the University of Colorado School of Medicine (RMADC at UCSOM) Longitudinal Biomarker and Clinical Phenotyping Study

This study plans to establish a large bank of blood, cerebral spinal fluid (CSF), imaging,
and clinical data. These data and samples will be used for future research into the causes of
Alzheimer's disease (AD), Down Syndrome (DS) and other diseases that cause thinking and
memory problems. This future research will also study how treatments for these diseases work.
This research may help develop new treatments for some diseases of the nervous system and
help understand these diseases better.


Inclusion Criteria:

1. Persons with age-related MCI or AD according to clinical diagnosis, consistent with
NIA-AA diagnostic criteria

2. Individuals with DS according to clinical diagnosis, with cognitive ability sufficient
to follow directions, Age > 30 years

3. Non-DS community-dwelling controls, Age > 60 years

4. Non-pregnant mothers and fathers of DS individuals (controls)

5. Ability to complete baseline assessments

6. Has an informant (study partner) available to complete functional interviews/survey
measures annually

Exclusion Criteria:

- Presence of concomitant medical, neurological, or psychiatric illness or condition
that in the opinion of the investigators would confound interpretation of study
results. These include: Korsakoff encephalopathy; active substance abuse; hepatitis C;
opportunistic brain infection; brain tumor; active neoplastic disease (skin tumors
other than melanoma are not exclusionary; participants with stable prostate cancer may
be included at the discretion of the project director); multiple sclerosis; history of
clinically significant stroke; current evidence or history in the past 2 years of
focal brain lesion, head injury with loss of consciousness, or DSM-V criteria for any
major psychiatric disorder, including psychosis, major depression, bipolar disorder,
alcohol or substance abuse; blindness, deafness or any other disability which may
prevent the participant from participating or cooperating in the protocol.

- Presence of contraindication for MRI scan for Non-Down Syndrome participants
We found this trial at
1
site
13001 E. 17th Pl
Aurora, Colorado 80045
303-724-5000
University of Colorado Denver The University of Colorado Denver | Anschutz Medical Campus provides a...
?
mi
from
Aurora, CO
Click here to add this to my saved trials